Introduction {#s1}
============

Targeted therapy in cancer treatment refers to the application of special agents acting on specific molecular features of signal transduction pathways involved in the development of the cancerous phenotype. Erlotinib, gefitinib, sorafenib, sunitinib and lapatinib are all clinically used tyrosine kinase inhibitors (TKIs) targeting receptors and downstream members of the ERBB/RAS pathway [@pone.0059503-Gyorffy1]. Erlotinib and gefitinib are reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used in the treatment of non-small cell lung cancer. About 10% of the patients respond to the treatment in the European and Northern American population [@pone.0059503-Cohen1]. Lapatinib inhibits the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is approved for the treatment of breast cancer, where the overall response rate to this treatment is 24% [@pone.0059503-Gomez1]. Sorafenib inhibits RAF, VEGFR, PDGFR, Flt-3, c-Kit receptors. The partial response rate is 10%, when it is administered for patients with advanced renal-cell carcinoma [@pone.0059503-Escudier1]. Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Objective response rate is 31% in the first line treatment of renal cell carcinoma [@pone.0059503-Motzer1]. Because of the low overall response rates of 10--47% [@pone.0059503-Cohen2]--[@pone.0059503-Choueiri1], there is an increasing need for biomarkers predicting response to targeted therapy treatment.

Besides pharmacokinetic parameters, a tumor can deploy different molecular mechanisms to achieve resistance against targeted therapy agents: the target molecule may be subject to modification, downstream alterations of the pathway may lead to resistance against an agent targeting an upstream molecule, or other pathways may be activated which alternatively mediate cancer cell survival and proliferation. For example, the T790M mutation of the *EGFR* gene retains the ability of the receptor to activate the downstream pathway but simultaneously decreases binding of gefitinib and erlotinib to the receptor and thus leads to drug resistance [@pone.0059503-Zhou1]. *MET* amplification causes resistance against erlotinib and gefitinib through the activation of alternative pathways [@pone.0059503-Armato1]. Interleukine-8 can activate an alternative pathway leading to sunitinib resistance [@pone.0059503-Huang1]. Mutations of the genes of downstream members of the pathway can also contribute to resistance against targeted therapy agents, as described before in case of *KRAS* [@pone.0059503-Marks1], *PTEN* [@pone.0059503-Dave1], *BRAF* [@pone.0059503-DiNicolantonio1], and *PIK3CA* [@pone.0059503-SartoreBianchi1]. When a downstream component of the signaling system activates the pathway, inhibition by the blockade of an upstream member was shown to be ineffective. These downstream changes can be used as negative predictors for agents acting upstream of this addictive element of the pathway, as described before for *KRAS* [@pone.0059503-Pao1]. If *KRAS* harbors an activating mutation, agents acting on EGFR will not have any effect on tumor growth [@pone.0059503-Jackman1].

Previous studies have already described that the use of gene expression data, coupled with *in vitro* drug sensitivity assays, can be used to develop signatures that could classify response to conventional anticancer agents [@pone.0059503-Lugthart1], [@pone.0059503-Gyorffy2]. In another study, a panel of cancer cell lines was treated with dasatinib, a multitarget kinase inhibitor, and sensitivity to the drug was measured. In parallel, expression data generated from the same panel of cell lines was used to develop a signature to predict sensitivity to the drug [@pone.0059503-Huang2]. In a different study, a panel of lung cancer cell lines was used to develop gene expression signatures that predict sensitivity to the EGFR inhibitors gefitnib [@pone.0059503-Coldren1] and erlotinib [@pone.0059503-Balko1]. Finally, the common significant genes of an *in vitro* and an *in vivo* study were able to predict response to rapamycin [@pone.0059503-Akcakanat1]. Although focused on single therapeutic agents in one type of cancer, these studies already demonstrated the power of gene expression profiles to predict response to a specific agent.

In this present study, we took a broader approach aiming to identify gene signatures associated with intrinsic resistance against 5 already approved tyrosine kinase inhibitors targeting the ERBB/RAS-pathway. To obtain new predictive biomarkers, we correlated the sensitivity of 45 cell lines representing 15 different cancer entities to expression patterns. The best performing candidate genes were then validated using qRT-PCR. Finally, clinical validation was performed using immunohistochemistry based on tissue microarrays on a set of renal cell carcinomas from patients treated with sunitinib.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

The approval number for the sample collection by the National Scientific and Research Ethics Committee (ETT-TUKEB) (Hungary) is \#185/2007. General informed consent was obtained before the surgery. The National Scientific and Research Ethics Committee did not request a specific written permission, because, it was a retrospective study, and the patients were handled anonymously.

Cell Culture {#s2b}
------------

We obtained 45 ATCC cell lines. Before selection, the absence of *KRAS* mutation in the cell lines was confirmed using the Catalogue of Somatic Mutations in Cancer (search done on the 25^th^ of June 2010). The cells were cultured according to the ATCC protocols (<http://www.lgcstandards-atcc.org/>). Additionally, antibiotics (Penicillin-streptomycin, Invitrogen, cat. no.: 15070-063, Amphotericin B, Invitrogen, cat. no.: 15290-026) were added. The cell lines are summarized in [**Table 1**](#pone-0059503-t001){ref-type="table"}. An overview of the study is presented in [**Figure 1**](#pone-0059503-g001){ref-type="fig"}.

![Overview of the study.\
Boxes with grey background represent training steps, while white background represents validation steps.](pone.0059503.g001){#pone-0059503-g001}

10.1371/journal.pone.0059503.t001

###### Resistance characteristics of the 45 cell lines investigated.

![](pone.0059503.t001){#pone-0059503-t001-1}

  Cell line       Origin        ATCC       lapatinib     erlotinib     sorafenib     sunitinib      gefitinib                                                               
  ----------- -------------- ---------- --------------- ----------- --------------- ------------ --------------- -------------- --------------- ----------- --------------- -----------
  CCRF-CEM         ALL        CCL-119     **SW-948**     **0,26**    **NCI-H441**    **−0,11**     **NCI-H69**     **−1,53**       **A-375**     **−0,15**    **Hep-3B**     **−0,09**
  MOLT-4           ALL        CRL-1582     **K-562**     **0,43**     **HCT-15**     **−0,08**    **NCI-H441**     **−1,25**       **CAOV3**     **0,07**     **HCT-15**     **0,06**
  K-562         Bonemarrow    CCL-243    **NCI-H358**    **0,48**      **CAOV3**     **−0,02**      **A-375**      **−1,04**      **HCT-15**     **0,08**     **SW-403**     **0,11**
  SK-N-AS         Brain       CRL-2137     **HCT-8**     **0,48**     **SW-948**      **0,09**      **CAOV3**      **−0,99**      **SW-948**     **0,21**      **C-4II**     **0,18**
  BT-20           Breast       HTB-19     **HCT-15**     **0,49**      **A-375**      **0,22**     **Hep-3B**      **−0,91**     **NCI-H441**    **0,31**    **NCI-H358**    **0,22**
  MCF-7           Breast       HTB-22     **HT-1080**    **0,54**    **NCI-H1993**    **0,24**      **C-4I**       **−0,68**     **NCI-H358**    **0,33**     **NCI-H69**    **0,23**
  RAJI         Burkitt's L     CCL-86    **NCI-H441**    **0,56**    **NCI-H1650**    **0,28**     **SW-620**      **−0,63**      **SW-620**     **0,35**      **WIDR**      **0,28**
  C-33A        CervixUteri     HTB-31      **MCF-7**     **0,62**    **NCI-H358**     **0,30**     **HT-1080**     **−0,58**      **SW-480**     **0,38**      **CAOV3**     **0,29**
  C-4I         Cervix Uteri   CRL-1594     **CAOV3**     **0,65**      **C-4II**      **0,31**     **HCT-15**      **−0,57**       **MCF-7**     **0,39**     **SNU-449**    **0,29**
  C-4II        Cervix Uteri   CRL-1595    **SNU-475**    **0,65**     **SW-480**      **0,39**     **DMS-79**      **−0,53**       **HCT-8**     **0,41**     **HT-1080**    **0,29**
  HCT-15          Colon       CCL-225     **Hep-3B**     **0,66**    **NCI-H661**     **0,42**      **C-4II**      **−0,50**       **A-427**     **0,41**      **A-375**     **0,30**
  HCT-8           Colon       CCL-244    **NCI-H1650**   **0,71**     **SNU-449**     **0,43**    **NCI-H1993**    **−0,45**      **Hep-3B**     **0,43**      **K-562**     **0,31**
  SW-403          Colon       CCL-230      **A-375**     **0,73**      **C-4I**       **0,47**     **SW-480**      **−0,41**       **C-4II**     **0,43**      **HCT-8**     **0,34**
  SW-480          Colon       CCL-228       **HOS**      **0,73**     ***K-562***    ***0,48***     *SHP-77*      **−** *0,36*   **NCI-H1650**   **0,44**     *NCI-H661*      *0,36*
  SW-620          Colon       CCL-227      **BT-20**     **0,74**      *SNU-475*       *0,50*        *K-562*      **−** *0,34*     *HT-1080*      *0,51*        *MCF-7*       *0,41*
  SW-948          Colon       CCL-237      *SHP-77*       *0,77*        *MCF-7*        *0,51*        *A-427*      **−** *0,33*     *NCI-H82*      *0,51*        *C-4I*        *0,41*
  WIDR            Colon       CCL-218     *CCRF-CEM*      *0,78*       *Hep-3B*        *0,51*        *HCT-8*      **−** *0,31*      *ES-2*        *0,51*      *CCRF-CEM*      *0,43*
  HT-1080      Fibrosarcoma   CCL-121      *SNU-449*      *0,78*      *CCRF-CEM*       *0,55*      *NCI-H358*     **−** *0,30*    *CCRF-CEM*      *0,51*       *SNU-475*      *0,47*
  A-498           Kidney       HTB-44       *C-4II*       *0,78*       *NCI-H69*       *0,55*       *SW-403*      **−** *0,28*     *SNU-475*      *0,51*       *SW-620*       *0,47*
  Hep-3B          Liver       HB-8064     *NCI-H1993*     *0,82*       *SW-403*        *0,55*       *SNU-475*     **−** *0,28*      *WIDR*        *0,53*       *NCI-H82*      *0,47*
  SNU-182         Liver       CRL-2235     *SW-480*       *0,82*         *HOS*         *0,58*      *COLO-668*     **−** *0,25*    *NCI-H1993*     *0,54*       *SW-480*       *0,48*
  SNU-423         Liver       CRL-2238      *C-33A*       *0,87*       *HT-1080*       *0,58*      *CCRF-CEM*     **−** *0,19*     *NCI-H69*      *0,56*        *ES-2*        *0,51*
  SNU-449         Liver       CRL-2234      *WIDR*        *0,88*        *C-33A*        *0,59*       *MOLT-4*      **−** *0,18*       *HOS*        *0,59*      *NCI-H1993*     *0,51*
  SNU-475         Liver       CRL-2236     *AN3-CA*       *0,89*       *AN3-CA*        *0,60*        *MCF-7*      **−** *0,16*     *SNU-449*      *0,60*      *NCI-H441*      *0,51*
  A-427            Lung        HTB-53      *SNU-423*      *0,90*        *ES-2*         *0,61*      *NCI-H1975*    **−** *0,14*      *C-4I*        *0,61*        *C-33A*       *0,53*
  COLO-668         Lung       87061209      *A-498*       *0,91*       *SW-620*        *0,61*       *SW-948*      **−** *0,12*     *MOLT-4*       *0,61*       *DMS-79*       *0,54*
  DMS-114          Lung       CRL-2066    *NCI-H661*      *0,95*        *BT-20*        *0,67*       *SNU-423*     **−** *0,12*      *K-562*       *0,63*       *SNU-182*      *0,57*
  DMS-79           Lung       CRL-2049     *SW-403*       *0,96*       *NCI-H82*       *0,68*       *SNU-449*     **−** *0,11*     *AN3-CA*       *0,63*       *SHP-77*       *0,64*
  NCI-H358         Lung       CRL-5807      *C-4I*        *0,98*        *WIDR*         *0,70*        *C-33A*      **−** *0,11*     *SNU-182*      *0,66*       *MOLT-4*       *0,65*
  NCI-H441         Lung       HTB-174      *DMS-114*      *0,98*        MOLT-4          0,73         *WIDR*       **−** *0,11*      *BT-20*       *0,66*        *RAJI*        *0,65*
  NCI-H661         Lung       HTB-183      **RAJI**      **0,99**      **A-498**      **0,73**      *NCI-H82*     **−** *0,09*    *COLO-668*      *0,71*      *NCI-H1650*     *0,67*
  NCI-H69          Lung       HTB-119     **SNU-182**    **1,01**     **HEC-1-B**     **0,73**      *SNU-182*     **−** *0,08*     **A-498**     **0,72**      **A-427**     **0,69**
  NCI-H82          Lung       HTB-175    **ChaGo-K-1**   **1,01**     **SNU-423**     **0,81**     *ChaGo-K-1*    **−** *0,07*    **SK-N-AS**    **0,72**      **BT-20**     **0,69**
  SHP-77           Lung       CRL-2195    **NCI-H82**    **1,02**    **NCI-H1975**    **0,82**       *RAJI*       **−** *0,05*     **RAJI**      **0,72**     **AN3-CA**     **0,71**
  ChaGO-K-1        Lung       HTB-168     **MOLT-4**     **1,03**     **DMS-79**      **0,82**       *BT-20*      **−** *0,01*   **NCI-H1975**   **0,73**     **SNU-423**    **0,73**
  NCI-H1650        Lung       CRL-5883    **NCI-H69**    **1,03**      **RAJI**       **0,82**      *DMS-114*        *0,00*      **ChaGo-K-1**   **0,78**    **NCI-H1975**   **0,74**
  NCI-H1975        Lung       CRL-5908     **ES-2**      **1,05**    **ChaGo-K-1**    **0,83**        *HOS*          *0,01*       **SNU-423**    **0,80**      **A-498**     **0,80**
  NCI-H1993        Lung       CRL-5909   **NCI-H1975**   **1,08**     **DMS-114**     **0,89**    **NCI-H1650**     **0,14**     **NCI-H661**    **0,88**    **ChaGo-K-1**   **0,81**
  RD              Muscle      CCL-136     **SK-N-AS**    **1,10**     **SNU-182**     **0,90**       **RD**         **0,20**      **DMS-79**     **0,89**       **HOS**      **0,87**
  CAOV3           Ovary        HTB-75      **A-427**     **1,10**    **COLO-668**     **0,91**     **SK-N-AS**      **0,20**      **SHP-77**     **0,90**     **DMS-114**    **0,93**
  ES-2            Ovary       CRL-1978      **RD**       **1,12**      **HCT-8**      **0,95**      **ES-2**        **0,21**       **C-33A**     **0,91**     **SK-N-AS**    **1,04**
  HOS            Sarcoma      CRL-1543   **COLO-668**    **1,13**      **A-427**      **0,98**     **HEC-1-B**      **0,31**      **DMS-114**    **0,92**     **HEC-1-B**    **1,07**
  A375             Skin       CRL-1619    **DMS-79**     **1,20**     **SK-N-AS**     **1,00**    **NCI-H661**      **0,32**        **RD**       **0,96**       **RD**       **1,28**
  AN3-CA          Uterus      HTB-111     **HEC-1-B**    **1,31**       **RD**        **1,01**      **A-498**       **0,49**      **HEC-1-B**    **0,98**    **COLO-668**    **1,34**
  HEC-1-B         Uterus      HTB-113     **SW-620**     **1,31**     **SHP-77**      **1,04**     **AN3-CA**       **0,61**      **SW-403**     **1,08**     **SW-948**     **1,45**

For each drug, the cell lines are ranked based on their RI values (green: low, red: high, yellow: intermediate RI) at the C2 concentration. The panels of resistant- and sensitive-designated cell lines are marked by bold and the intermediate cell lines are marked by italic formatting for each agent.

DNA Isolation and Quality Control {#s2c}
---------------------------------

DNA was isolated using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany, cat. no.: 69506) according to the product user's guide. Quantity and quality of the DNA were tested by using a Nanodrop 1000 system (BCM, Houston, TX, USA). DNA (A260) and protein (A280) concentrations and sample purity (260/280 ratio) were measured and only high quality DNA was used for further analysis. DNA was stored at −80°C.

Authentication of Cell Lines {#s2d}
----------------------------

Authentication was performed for cell lines obtained more than 4 years ago from ATCC using short tandem repeat (STR) analysis of 10 specific loci in the human genome and a mouse specific marker. Authentication was carried out by StemElite ID System at the Fragment Analysis Facility, Johns Hopkins University (Baltimore, USA). STR profiles of the applied cell lines were compared to the STR profile database of the Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures (<http://www.dsmz.de>). All cell lines included in this study were contamination-free.

Resistance Tests {#s2e}
----------------

Drugs were used in their commercially available form, and were applied to the cells in 3 concentrations (C1, C2, C3). C1 = 0.1\*C2 and C3 = 10\*C2. Concentration C2 was deduced from the clinically used doses (see [**Table 2**](#pone-0059503-t002){ref-type="table"}).

10.1371/journal.pone.0059503.t002

###### Concentrations used in the cell lines to measure the resistance indexes.
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  Drug         Concentration (µM)          
  ----------- -------------------- ------- -------
  lapatinib          2.867          28.67   286.7
  sunitinib          0.124          1.24    12.4
  sorafenib          1.147          11.47   114.7
  erlotinib          0.508          5.08    50.8
  gefitinib          0.745          7.45    74.5

The MTT assay (Roche, Cat. No.: 11465007001), was used to test the anti-proliferative effect of reagents and cell viability. In each experiment, 2000 cells/well were seeded in 100 µl medium onto 96-well plates. After one day incubation, precontrol cells were stained. At the same time, the cultures were treated with all 5 studied drugs at C1, C2 and C3 concentrations. On the fifth day the experiment was terminated and the cells were stained. The absorbance was read with a Thermo Scientific Multiskan® FC. The absorbance measured at 595 nm was corrected with the background measured at 690 nm. All measurements were repeated three times and for the calculation of the resistance index (RI) values, the averages of the 3 measurements were used. The resistance index (RI) was computed by the formula [@pone.0059503-Gyorffy3]:where N~pre~ is the medium absorbance value of precontrol (representing the number of cells at the beginning of the treatment), N~post~ is the medium absorbance value of control (representing the number of cells at the end of the treatment with vehicle treatment only), and N~2~ is the medium absorbance value of treated cells treated with the C2 concentration of the studied drug. C1 and C3 concentrations were used as internal controls to monitor the dynamic range of the agents. Only cell lines that fulfilled the quality criteria of N~post~\>N~pre~ and deviation in cell growth within repetitions \<15% were included in the evaluation.

Feature Selection {#s2f}
-----------------

Raw microarray data for the cell lines were generated in the GSK caArray project (<ftp://caftpd.nci.nih.gov/pub/caARRAY/transcript_profiling>). caArray was developed using the caBIG compatibility guidelines, as well as the Microarray Gene Expression Data (MGED) society standards for microarray data. After downloading, the raw.CEL files were MAS5 normalized in the R statistical environment ([www.r-project.org](http://www.r-project.org)) using the affy Bioconductor library [@pone.0059503-Gautier1]. MAS5 ranked among the best normalization methods when compared to the results of qRT-PCR measurements in our recent study [@pone.0059503-Gyorffy4]. Each cell line was measured on the microarrays by triplicates - in the final step of the pre-processing the average of these were computed. As probe sets with very low abundance are not only unlikely to hold biological significance, but are also error prone, we made a filtering to retain only probe sets with an average expression over 100 and maximal expression over 1000. The complete normalized database is presented in **[Table S1](#pone.0059503.s001){ref-type="supplementary-material"}**.

The complete dataset consisting of the expression profiles has been arranged into 2 classes, according to the resistance properties of the cell lines. Intermediate cell lines were excluded. This selection procedure resulted in 5 datasets, which were treated as autonomous classification tasks. To obtain the list of genes best correlated to resistance, we used Significance Analysis of Microarrays (SAM) [@pone.0059503-Tusher1] and rank products [@pone.0059503-Breitling1], [@pone.0059503-Breitling2]. While SAM is the most widely used method, rank products were found to deliver the best performance in a setting similar to our project with low sample size in an earlier summary of available feature selection methods [@pone.0059503-Jeffery1]. The efficacy of the gene sets to discriminate resistant and sensitive cell lines was computed using Prediction Analysis of Microarrays [@pone.0059503-Tibshirani1]. The R file of the used statistical analysis is available in the supplemental material as Script S1.

To assess the capability of the gene-sets to predict survival, we searched in Pubmed GEO for datasets with available clinical follow-up where cancer patients were treated with one of the five investigated agents. Finally, to search for gene lists similar to our genes and to identify genes correlated to the identified genes, we used the CCancer search engine [@pone.0059503-Dietmann1].

RNA Isolation and Quality Control {#s2g}
---------------------------------

After homogenization using Qiashredder, RNA was isolated using the Qiagen RNeasy kit (Qiagen, Hilden, Germany) according to the product user's guide. Quantity and quality of the isolated RNA was tested by using a Nanodrop 1000 system (BCM, Houston, TX, USA) and by gel electrophoresis using an Agilent Bioanalyzer system (Agilent Technologies Inc., Santa Clara, CA, USA). RNA (A260) and protein (A280) concentrations and sample purity (260/280 ratio) were measured. Only high quality, intact total RNA was accepted for samples which also showed regular 18S and 28S ribosomal RNA bend pattern on the Bioanalyzer analysis. RNA was kept at -80°C until RT-PCR measurement.

TaqMan Assay {#s2h}
------------

TaqMan real-time PCR was used to measure the expression of 95 selected genes (plus one housekeeping gene) using a Micro Fluidic Card System (Applied Biosystems, Foster City, CA, USA) in 40 cell lines. The measurements were performed using an ABI PRISM® 7900HT Sequence Detection System as described in the products User Guide. The genes were selected to include the top genes correlated to resistance to the various agents. Additionally, based on a literature search, a set of genes correlated to targeted therapy resistance and members of the EGFR/RAS pathway were also added for additional analyses. The list of included genes is presented in **[Table S2](#pone.0059503.s002){ref-type="supplementary-material"}**.

Data Analysis of the RT-PCR Measurements {#s2i}
----------------------------------------

For primary data analysis the SDS 2.2 software was used. The delta Ct values (which represent the expression normalized to ribosomal 18S expression) were grouped according to the resistance characteristics against the various agents into groups. Then, student's t-test was performed to compare the expression of the gene in the various groups independently. Statistical significance was set at p\<0.05.

Renal Cell Carcinoma (RCC) Sample Collection {#s2j}
--------------------------------------------

Patients were treated at the Department of Urology, Semmelweis University, Budapest, Hungary between 2005 and 2010. Samples were collected according to state-of-the-art pathology protocol from all patients operated for renal cell cancer. However, only patients with later metastatic disease were included in present study, as only these patients received a targeted therapy treatment. The two agents in clinical use for metastatic RCC are sunitinib and sorafenib. Of these, sunitinib is administered in the first line setting, thus, these patients were chosen for the immunohistochemical analyses. Tissue microarrays (TMA) of all FFPE samples were constructed with the Tissue Micro-Array Builder instrument (Histopathology Ltd., Pécs, Hungary). In the TMAs, duplicates of 2 mm wide cores were used of each tumor representing their most relevant areas according to histopathology.

Immunohistochemistry {#s2k}
--------------------

The immunohistochemical (IHC) reactions were performed on 4 µm thick sections obtained from TMA blocks. After deparaffinization, the slides were heated in a microwave oven in Target Retrieval Solution (DAKO, Carpenteria, CA, USA) for 30 minutes. An automated Ventana Benchmark immunostainer system was used according to the protocol '880' (and '870' for LGALS8) provided by the manufacturer (Ventana Medical Systems Inc., Tucson, AZ, USA). RAB17 (dilution, 1∶200), LGALS8 (1∶50), EpCam (1∶100) and CD9 (1∶300) antibodies were used for staining. The tissues were counterstained with Mayer's hemalaun (00-8011, Zymed Laboratories Inc.). Positive controls and negative control tissues were applied in all IHC runs. In case of CD9, LGALS8, RAB17 cytoplasmic reaction, for EpCAM membranous staining was accepted as proper localization.

The stained slides were digitalized with a slide scanner (Mirax MIDI Scan, 3DHistech Ltd., Budapest, Hungary), and intensity of the reaction (0: negative reaction, +1: weak positivity, +2: moderate positivity, +3: strong reaction) and frequency of positively stained cells (0∶0--1%, 1∶1--5%, 2∶5--10%, 3∶10--20%, 4∶20--33%, 5∶33--50%, 6∶50--66%, 7∶66--80%, 8∶80--100%) were evaluated separately. Finally, correlation between 25-percentile survival groups as well as Kaplan-Meier survival plots based on grouping using the median were computed in WinStat for Excel (R. Fitch Software, Bad Krozingen, Germany).

Results {#s3}
=======

Resistance Tests {#s3a}
----------------

The resistance of each cell line was measured in triplicates for each of the three concentrations of the five agents. Then, the cell lines were ranked based on their RI values. An intermediate RI value was designated as being within the median RI value +/−10% of the RI range. Cell lines exhibiting higher RIs were designated as resistant, and cell lines with lower RIs as sensitive. A complete overview of the separation of cell lines into groups is depicted in [**Table 1**](#pone-0059503-t001){ref-type="table"} **.**

Identification of Discriminatory Genes {#s3b}
--------------------------------------

For the classification, the genes were filtered to include only those which achieved an at least 2-fold difference in the average expression compared between cell lines designated as sensitive or resistant. Then, feature selection with SAM and rank products was performed. Only those genes were accepted as significant, which achieved a false discovery rate below 20%. The complete list of significant genes is listed in **[Table S3](#pone.0059503.s003){ref-type="supplementary-material"}**.

The accuracy of the classification in the leave-one-out cross-validation setting using all genes in the cell lines resulted in an efficiency of 92.8% in PAM (cell lines with intermediate resistances were excluded). The use of the top 100 genes identified by rank products resulted in 79% correct predictions. The correct classifications using the top 100 rank products identified genes are presented in blue and incorrect classifications in red in **[Table S4](#pone.0059503.s004){ref-type="supplementary-material"}**.

Although the investigated agents are in clinical use already for over 7 years, we were unable to find published data sets suitable for meta-analysis of the identified gene-set. Thus, we could not perform an *in silico* validation on prediction of clinical response or survival. Using CCancer, all together 27 publications with overlapping gene sets have been identified. These are presented in **[Table S5](#pone.0059503.s005){ref-type="supplementary-material"}**.

TaqMan Validation of Cell Line-derived Gene Profiles {#s3c}
----------------------------------------------------

TaqManq RT-PCR results are summarized in [**Table 3**](#pone-0059503-t003){ref-type="table"}. 45 of the 63 genes associated with resistance in the feature selection using the microarray data were confirmed below p\<0.05 and 23 of these below p\<0.01. The highest significance was achieved by *ITGB4* (p = 0.005) of the erlotinib-resistance associated, by *IADA* (p = 0.003) of the gefitinib-associated genes, by *FAT4* (p = 0.011) of the sorafenib associated genes and by *FURIN* and *ME1* (p = 0.011) of the lapatinib-associated genes. Several genes were significantly confirmed of the sunitinib-resistance gene signature including *KRT18* (p = 0.001), *LGALS8* (p = 0.019), *RAB17* (p = 0.002), *CD9* (p = 0.002) and *PPL* (p = 0.001). Meanwhile, only 7 of the 32 genes previously described in the literature as associated with resistance against the targeted therapy agents were confirmed. The complete normalized result of the TaqMan assays is available as **[Table S6](#pone.0059503.s006){ref-type="supplementary-material"}**.

10.1371/journal.pone.0059503.t003

###### Validation of the top genes by TaqMan RT-PCR in the cell lines.

![](pone.0059503.t003){#pone-0059503-t003-3}

  Symbol                                                            TaqMan ID     Affymetrix ID                             Gene name                               p value    
  -------------------------------------------------------------- --------------- --------------- --------------------------------------------------------------- ------------- -----------
  **Erlotinib**                                                                                                                                                                
  B3GNT3                                                          Hs00429537_m1     204856_at     UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3    **0.021**   
  CAST                                                            Hs00156280_m1   208908_s\_at                             calpastatin                             **0.030**   
  CLMN                                                            Hs00226865_m1   221042_s\_at                calmin (calponin-like, transmembrane)                **0.023**   
  ERBB3                                                           Hs00176538_m1   202454_s\_at      v-erb-b2 erythroblastic leukemia viral oncogene homolog 3      **0.016**   
  FXYD5                                                           Hs00204319_m1   218084_x\_at          FXYD domain containing ion transport regulator 5           **0.016**   
  ITGB4                                                           Hs00236216_m1   204990_s\_at                          integrin, beta 4                           **0.005**   
  LGALS3                                                          Hs00173587_m1   208949_s\_at               lectin, galactoside-binding, soluble, 3               **0.016**   
  NEAT1                                                           Hs01008264_s1   214657_s\_at              nuclear paraspeckle assembly transcript 1              **0.019**   
  PRSS22                                                          Hs00223188_m1     205847_at                         protease, serine, 22                         **0.023**   
  S100A10                                                         Hs00741221_m1     200872_at                   S100 calcium binding protein A10                   **0.015**   
  SECTM1                                                          Hs00171088_m1   213716_s\_at                    secreted and transmembrane 1                     **0.026**   
  TFAP2C                                                          Hs00231476_m1     205286_at                    transcription factor AP-2 gamma                   **0.004**   
  **Gefitinib**                                                                                                                                                                
  ADA                                                             Hs01110945_m1   216705_s\_at                         adenosine deaminase                         **0.003**   
  COL5A1                                                          Hs00609088_m1     212489_at                       collagen, type V, alpha 1                      **0.018**   
  SLC2A6                                                          Hs01115485_m1     220091_at                   solute carrier family 2, member 6                  **0.027**   
  **Sorafenib**                                                                                                                                                                
  FAT4                                                            Hs01570491_m1     219427_at                    FAT tumor suppressor homolog 4                    **0.011**   
  GNG11                                                           Hs00914578_m1     204115_at       guanine nucleotide binding protein (G protein), gamma 11       **0.068**   
  TUSC3                                                           Hs00954406_m1   213423_x\_at                    tumor suppressor candidate 3                     **0.021**   
  **Sunitinib**                                                                                                                                                                
  CD9                                                             Hs00233521_m1     201005_at                             CD9 molecule                             **0.002**   
  EPCAM                                                           Hs00158980_m1   201839_s\_at                  epithelial cell adhesion molecule                  **0.009**   
  KRT18                                                           Hs01941416_g1   201596_x\_at                             keratin 18                              **0.001**   
  KRT8                                                            Hs01630795_s1   209008_x\_at                              keratin 8                              **0.041**   
  LGALS8                                                          Hs00374634_m1   208934_s\_at               lectin, galactoside-binding, soluble, 8               **0.019**   
  LSR                                                             Hs00210880_m1   208190_s\_at              lipolysis stimulated lipoprotein receptor              **0.046**   
  PPL                                                             Hs00160312_m1     203407_at                              periplakin                              **0.001**   
  RAB17                                                           Hs00940833_m1     218931_at                   RAB17, member RAS oncogene family                  **0.002**   
  SAT1                                                            Hs00161511_m1   203455_s\_at             spermidine/spermine N1-acetyltransferase 1              **0.003**   
  SIGIRR                                                          Hs00222347_m1     52940_at      single immunoglobulin and toll-interleukin 1 receptor domain     **0.004**   
  **Lapatinib**                                                                                                                                                                
  FURIN                                                           Hs00965485_g1     201945_at            furin (paired basic amino acid cleaving enzyme)           **0.011**   
  ME1                                                             Hs00159110_m1   204059_s\_at            malic enzyme 1, NADP(+)-dependent, cytosolic             **0.011**   
  TMOD3                                                           Hs00205710_m1   220800_s\_at                           tropomodulin 3                            **0.004**   
  **Genes associated with resistance against multiple agents**                                                                                                                 
  AGR2                                                            Hs00180702_m1     209173_at                      anterior gradient homolog 2                    *sunitinib*   **0.013**
  ANXA3                                                           Hs00971411_m1     209369_at                              annexin A3                             *gefitinib*   **0.040**
                                                                                                                                                                  *sorafenib*   **0.032**
                                                                                                                                                                  *sunitinib*   **0.001**
                                                                                                                                                                  *lapatinib*   **0.045**
  CDH1                                                            Hs01023894_m1   201130_s\_at                   cadherin 1, type 1, E-cadherin                   *erlotinib*   **0.050**
                                                                                                                                                                  *sunitinib*   **0.002**
  CLDN7                                                           Hs00600772_m1     202790_at                               claudin 7                             *sunitinib*   **0.013**
  COL3A1                                                          Hs00943809_m1   215076_s\_at                     collagen, type III, alpha 1                    *gefitinib*   **0.005**
                                                                                                                                                                  *sorafenib*   **0.000**
                                                                                                                                                                  *sunitinib*   **0.009**
  FXYD3                                                           Hs00254211_m1   202488_s\_at          FXYD domain containing ion transport regulator 3          *erlotinib*   **0.037**
                                                                                                                                                                  *sunitinib*   **0.016**
  GJA1                                                            Hs00748445_s1     201667_at                 gap junction protein, alpha 1, 43 kDa               *sunitinib*   **0.000**
  KRT19                                                           Hs00761767_s1     201650_at                              keratin 19                             *erlotinib*   **0.032**
                                                                                                                                                                  *sorafenib*   **0.029**
                                                                                                                                                                  *sunitinib*   **0.000**
  LHX2                                                            Hs00180351_m1   211219_s\_at                           LIM homeobox 2                           *sorafenib*   **0.021**
  MPZL2                                                           Hs00170684_m1     203780_at                      myelin protein zero-like 2                     *sorafenib*   **0.036**
                                                                                                                                                                  *sunitinib*   **0.008**
  NEFH                                                            Hs00606024_m1     33767_at                    neurofilament, heavy polypeptide                  *erlotinib*   **0.001**
                                                                                                                                                                  *sunitinib*   **0.002**
  RAB25                                                           Hs00220628_m1     218186_at                   RAB25, member RAS oncogene family                 *erlotinib*   **0.006**
                                                                                                                                                                  *gefitinib*   **0.011**
                                                                                                                                                                  *sorafenib*   **0.015**
                                                                                                                                                                  *sunitinib*   **0.007**
  S100P                                                           Hs00195584_m1     204351_at                    S100 calcium binding protein P                   *sunitinib*   **0.024**
  TACSTD2                                                         Hs00242741_s1   202286_s\_at            tumor-associated calcium signal transducer 2            *sunitinib*   **0.037**
  **confirmed literature-based genes**                                                                                                                                         
  ERBB2                                                           Hs01001580_m1   216836_s\_at                          v-erb-b2 oncogene                         *lapatinib*   **0.034**
  TGFA                                                            Hs00608187_m1     205016_at                   transforming growth factor, alpha                 *lapatinib*   **0.034**
  ANGPT1                                                          Hs00375822_m1   205608_s\_at                           angiopoietin 1                           *sunitinib*   **0.036**
  IFNG                                                            Hs00989291_m1     210354_at                           interferon, gamma                         *sunitinib*   **0.024**
  PDGFA                                                           Hs00964426_m1   205463_s\_at          platelet-derived growth factor alpha polypeptide          *sunitinib*   **0.044**
  AKT1                                                            Hs00178289_m1   207163_s\_at            v-akt murine thymoma viral oncogene homolog 1           *erlotinib*   **0.047**
                                                                                                                                                                  *lapatinib*   **0.041**
  COX2                                                            Hs00153133_m1     204748_at                            cyclooxygenase                           *sunitinib*   **0.034**

For the complete results of RT-PCR measurements refer to [Table S6](#pone.0059503.s006){ref-type="supplementary-material"}.

Some of the genes were associated with resistance against several agents. The highest significance of these was achieved by *COL3A1* (p\<0.001 in case of sorafenib-resistance), *GJA1* (p\<0.001 in case of sunitinib-resistance) and *KRT19* (p\<0.001 in case of sunitinib-resistance). We have also depicted the genes associated with resistance against multiple agents using a circus-plot (see [**Figure 2**](#pone-0059503-g002){ref-type="fig"}). Using this approach one can recognize the high number of genes associated with sunitinib resistance and the presence of only a single gene correlated to lapatinib resistance. Only two genes (*ANXA3* and *RAB25*) were correlated to intrinsic resistance against at least four agents.

![Circos plot of genes conferring multiple resistances.\
Circos plot of RT-PCR validated correlations for genes associated with resistance against multiple agents as identified by microarray analysis. The thickness of the ribbons correlate to the *log(p)* of the correlation (see [Table 2](#pone-0059503-t002){ref-type="table"}.). Note the high number of genes associated with sunitinib resistance and the single gene associated with lapatinib resistance. The two most informative genes are ANXA3 and RAB25, each associated with resistance against four agents.](pone.0059503.g002){#pone-0059503-g002}

IHC-based Validation in Renal Cell Carcinomas {#s3d}
---------------------------------------------

Altogether 39 sunitinib-treated patients with metastatic renal cell carcinoma were included in the study. The patient samples were collected before the administration of first-line TKI and are therefore similar to the measurement of gene expression in cell lines without treatment. The average age of the patients was 59 years, 63% of patients were female. The median overall survival is 14 months with 12/39 deaths. The average survival is 20 months. Partial metastasectomy was performed in case of seventeen patients. Representative images of the immunohistochemical staining for three proteins encoded by the identified genes are displayed in [**Figure 3**](#pone-0059503-g003){ref-type="fig"}. The detailed results in all samples for all genes are presented in **[Table S7](#pone.0059503.s007){ref-type="supplementary-material"}**.

![Immunohistochemistry.\
Representative examples of the immunhistochemical validation for CD9, EpCAM and LGALS8. Left column: normal kidney, right column: selected tumor tissue.](pone.0059503.g003){#pone-0059503-g003}

The increased staining intensity of LGALS8 (p = 0.026) and RAB17 (p = 0.018) and the frequency of positive cells for EpCAM (p = 0.01) and LGALS8 (p = 0.01) were correlated to improved survival. Meanwhile, CD9 - although showing a trend towards reduced survival in patients having increased staining intensity (p = 0.14) - was not significant. The Kaplan-Meier survival plot for EPCAM is depicted in [**Figure 4**](#pone-0059503-g004){ref-type="fig"}.

![Survival plots.\
Kaplan-Meier survival plots of sunitinib-treated metastatic RCC samples divided into two cohorts based on the median of EpCAM positive cells (p = 0.01).](pone.0059503.g004){#pone-0059503-g004}

Discussion {#s4}
==========

Targeted therapy agents acting via the ERBB/RAS pathway entered the mainstream cancer therapy guidelines. As still only 10--47% of patients respond to these therapies, it is of utmost importance to identify the drivers and potential markers of resistance. In our study we used 45 cancer cell lines and genome-wide gene expression signatures to identify potential new intrinsic biomarker genes. As a potential clinical application of our strategy, we validated the products of resistance-associated genes by IHC analysis in sunitinib-treated renal cell carcinomas.

We used a heterogeneous panel of cancer cell lines originating from lung (used TKIs include erlotinib and gefitinib), breast (lapatinib), renal (sorafenib and sunitinib), and liver (sorafenib). Cell lines with a known RAS mutation were excluded, since activating RAS mutations render the inhibition of upstream tyrosine kinases completely ineffective, as has been previously shown for colon cancer [@pone.0059503-Amado1]. The selection of cell lines enables identification of robust genes related to previously unidentified independent pathways.

In a recent study of Barretina et al, a large panel of cell lines was investigated to identify markers of sensitivity against a set of cytotoxic and targeted agents including three of the tyrosine kinase inhibitors used in present study (erlotinib, lapatinib and sorafenib) by measuring sensitivity at the IC50 and EC50 values [@pone.0059503-Barretina1]. To increase clinical relevance of cancer cell line testing, we used drug concentrations applied in clinical settings, as we expected to find the most reliable candidate markers at concentrations also achievable in patients [@pone.0059503-Minematsu1], [@pone.0059503-Widemann1]. The robustness of the approach using such pre-defined clinical concentrations is supported by the successful validation in a clinical cohort of sunitinib-treated patients.

We have found most cross-resistance associated genes related to sunitinib-resistance. Interestingly, so far only a few genes have been correlated with sunitinib-resistance in the literature while the number of candidate genes involved in resistance against the other agents is much larger. Therefore, we particularly focused on sunitinib resistance and performed immunohistochemical experiments on tumor samples to validate the discriminatory potential of four new candidate biomarkers, *LGALS8*, *RAB17*, *EpCAM*, and *CD9*.

Our first candidate gene *LGALS8* encodes a member of the galectin family. Galectins have been implicated in many functions including development, differentiation, cell-cell adhesion, cell-matrix interaction, growth regulation, apoptosis, and RNA splicing. Galectin-8 may also be involved in angiogenesis [@pone.0059503-Delgado1], and the expression is changed during hypolaryngeal and laryngeal tumor progression [@pone.0059503-Cludts1]. The second gene, *RAB17* is an epithelial cell-specific GTPase playing an important role in the regulation of membrane trafficking [@pone.0059503-Lutcke1]. The third gene, epithelial cell adhesion molecule (*EpCAM*) is a membrane protein with proto-oncogenic properties that is expressed in numerous cancers and is a promising anticancer drug target. It functions as a homotypic calcium-independent cell adhesion molecule. The release of the intracellular domain of the molecule results in the activation of the WNT pathway [@pone.0059503-Munz1]. High expression of *EpCAM* is associated with poor prognosis in gallbladder carcinoma [@pone.0059503-Varga1]. Finally, *CD9* plays a role in many cellular processes including differentiation, adhesion, signal transduction, growth, and in the suppression of cancer cell motility and metastasis. Miyake *et al* demonstrated that in patients with invasive ductal carcinomas the decreased expression of *CD9* protein was associated with poor prognosis [@pone.0059503-Miyake1]. The IHC staining results confirmed the correlations between *LGALS8, RAB17* and *EpCAM* and survival of renal carcinoma patients treated with sunitinib, while CD9 failed to achieve significant discriminatory potential.

According the results of our study these genes might represent new candidates to identify patients who may benefit from sunitinib therapy. While the immunohistochemical analysis validated 3 of the 4 biomarker candidates, a larger clinical study will be needed to rigorously estimate the power and confirm their clinical significance.

In the last decade, oncogene addiction has been acknowledged as one of the key factors of cancer evolution that can also mark pathways and genes for targeted therapies [@pone.0059503-Weinstein1]. However, due to the adaptation of cancer cells, drug addiction resulting from intensive treatment can overcome oncogene addiction as has been recently demonstrated in lung cancer cell lines [@pone.0059503-Suda1]. To understand these processes, the identification of genes, which share a functional role in the resistance against several targeted therapy agents, is of high priority.

Despite the similar mechanism of action, no gene was identified to be correlated with the sensitivity against all five agents in our study. Two genes, *ANXA3* and *RAB25* were related to four drugs. *Annexin 3* (ANXA3) plays a role in cellular growth and signal transduction [@pone.0059503-Jung1], and was previously linked to platinum resistance in ovarian cancer [@pone.0059503-Yan1]. The product of the *ANXA3* gene was also identified as one of the tyrosine-phosphorylation targets of EGFR by immunoprecipitation and western blotting [@pone.0059503-Ruan1]. *ANXA3* was identified as one of the four down-regulated genes involved in prostate cancer progression in a recent study that compared EGFR mutated and non-mutated tumours [@pone.0059503-PeraldoNeia1]. Our results imply the possibility of the involvement of *ANXA3* in collateral pathways enabling cancer cells to circumvent TKI therapy.

*RAB25* is a member of the RAS oncogene family. Loss of *RAB25* was associated with human colorectal adenocarcinomas [@pone.0059503-Nam1] and triple-negative breast cancer [@pone.0059503-Cheng1], but the gene has not yet been investigated in relationship to tyrosine kinase resistance. Future studies involving patients with simultaneously sequenced tyrosine kinases and RAS signaling pathway members are needed to assess its relevance in targeted therapy.

In summary, we present a comprehensive analysis pipeline for future studies of the investigated tyrosine kinase inhibitors. As a proof of principle we selected a set of genes associated with sunitinib resistance (the agent with the least published predictive biomarkers) for testing in a clinical cohort.
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**Cross validation.** The accuracy of the classification in the leave-one-out cross-validation setting using all genes in the cell lines resulted in an efficiency of 92.8% in PAM (cell lines with intermediate resistances were excluded). The use of the top 100 genes identified by rank products resulted in 79% correct predictions. The correct classifications using the top 100 rank products identified genes are presented in blue and incorrect classifications in red.
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**Immunohistochemistry.** The intensity and frequency of the CD9, epCAM, LGALS8 and RAB17 staining, with the number of the sample and the patient ID.
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